This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HELGE BADEN, M.D.; HARALD ENGBERG, M.D.; KURT IVERSEN, M.D.; TOVE JAGT, M.D.

AMA Arch Surg. 1960;81(4):608-610.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The demonstration of subclinical liver metastases in patients suffering from gastrointestinal cancer might prevent celiotomy in a number of cases. It was of great interest, therefore, when it was reported that the serum glutamic oxalacetic transaminase (S-GOT) was elevated in the presence of secondaries in the liver.

Studying a large series of patients, we tried to ascertain whether a raised S-GOT is a reliable criterion of the presence of subclinical hepatic metastases in patients with gastrointestinal cancer. At the same time, we had occasion to investigate the diagnostic value of an elevated serum alkaline phosphatase (SAP) as compared with S-GOT.

Previous Studies

Wroblewski and LaDue⁶ demonstrated a raised S-GOT in 13 out of 14 patients with histologically confirmed secondaries in the liver and in 10 out of 11 patients with clinical signs of hepatic secondaries. Studying the S-GOT values in 23 patients whose liver metastases were later proved by . . . [Full Text PDF of this Article]

Author Affiliations
Copenhagen, Denmark

From the Copenhagen City Hospital, Surgical Department I, and the Sønderbro Hospital, Medical Department, Copenhagen.

Footnotes
Submitted for publication Jan. 25, 1960.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?